Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- David S Shulman, MD
Dana-Farber Cancer Institute
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of California, San Francisco, Benioff Children'S Hospital
San Francisco, California, United States
- Dana Farber Cancer Institute
Boston, Massachusetts, United States
- Children'S Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
- Texas Children'S, Baylor College of Medicine
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Oct 2016
- Primary completion
- 31 Dec 2025
- Completion
- 31 Dec 2025
- Last update posted
- 11 Feb 2026
- Registered enrollment
- 26
- Registry id
- NCT02909777
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.